New bicyclic cannabinoid receptor-1 (CB1-R) antagonists

被引：38

作者：

Carpino, PA ^{[1
]}

Griffith, DA ^{[1
]}

Sakya, S ^{[1
]}

Dow, RL ^{[1
]}

Black, SC ^{[1
]}

Hadcock, JR ^{[1
]}

Iredale, PA ^{[1
]}

Scott, DO ^{[1
]}

Fichtner, MW ^{[1
]}

Rose, CR ^{[1
]}

Day, R ^{[1
]}

Dibrino, J ^{[1
]}

Butler, M ^{[1
]}

DeBartolo, DB ^{[1
]}

Dutcher, D ^{[1
]}

Gautreau, D ^{[1
]}

Lizano, JS ^{[1
]}

O'Connor, RE ^{[1
]}

Sands, MA ^{[1
]}

Kelly-Sullivan, D ^{[1
]}

Ward, KM ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, Groton Labs, Groton, CT 06340 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 03期

关键词：

cannabinoid receptor antagonists; CB1-R; 2,6-dihydropyrazolo[4,3-d]pyrimidin-7-one; 2,6-dihydro-pyrazolo[3,4-c]pyridin-7-one; 2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one; 1,9-dihydro-purin-6-one; obesity; conformational restriction;

D O I：

10.1016/j.bmcl.2005.10.019

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of conformationally constrained bicyclic derivatives derived from SR141716 was prepared and evaluated as hCB(1)-R antagonists and inverse agonists. Optimization of the structure-activity relationships around the 2,6-dihydro-pyrazolo[4,3 -d]pyrimidin-7-one derivative 2a led to the identification of two compounds with oral activity in rodent feeding models (2h and 4a). Replacement of the PP group in 2h with other bicyclic groups resulted in a loss of binding affinity. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：731 / 736

页数：6

共 14 条

[1] The endocannabinoid system: a general view and latest additions [J].

De Petrocellis, L ;

Cascio, MG ;

Di Marzo, V .

BRITISH JOURNAL OF PHARMACOLOGY, 2004, 141 (05) :765-774

[2]

DEVANE WA, 1988, MOL PHARMACOL, V34, P605

[3] The cannabinoid system: a role in both the homeostatic and hedonic control of eating? [J].

Harrold, JA ;

Williams, G .

BRITISH JOURNAL OF NUTRITION, 2003, 90 (04) :729-734

[4]

HERKENHAM M, 1995, CANNABINOID RECEPTOR, P145

[5] Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: Development of central cannabinoid receptor ligands with lower lipophilicity [J].

Katoch-Rouse, R ;

Pavlova, OA ;

Caulder, T ;

Hoffman, AF ;

Mukhin, AG ;

Horti, AG .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (04) :642-645

[6]

Lange JHM, 2004, CURR OPIN DRUG DISC, V7, P498

[7] 3-FLUORO-1-HYDROXYPROPAN-2-ONE (FLUOROHYDROXYACETONE) AND SOME ESTERS - SYNTHESES AND EFFECTS IN BDF1 MICE [J].

PERO, RW ;

BABIARZTRACY, P ;

FONDY, TP .

JOURNAL OF MEDICINAL CHEMISTRY, 1977, 20 (05) :644-647

[8]

Pertwee RG, 1999, CURR MED CHEM, V6, P635

[9] SR141716A, A POTENT AND SELECTIVE ANTAGONIST OF THE BRAIN CANNABINOID RECEPTOR [J].

RINALDICARMONA, M ;

BARTH, F ;

HEAULME, M ;

SHIRE, D ;

CALANDRA, B ;

CONGY, C ;

MARTINEZ, S ;

MARUANI, J ;

NELIAT, G ;

CAPUT, D ;

FERRARA, P ;

SOUBRIE, P ;

BRELIERE, JC ;

LEFUR, G .

FEBS LETTERS, 1994, 350 (2-3) :240-244

[10]

SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219

← 1 2 →